Clinical trials
Advanced Liver Cancer clinical trials
Below are recruiting advanced liver cancer clinical trials, each written for real people, not researchers. We’re tracking 862 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT03579836RecruitingPhase 1/Phase 2
Test BEY1107 plus gemcitabine for pancreatic cancer
This early study tests whether BEY1107 given alone or with gemcitabine can be used safely and may help shrink pancreatic cancer tumors. It mainly looks at safety, side effects, and signs of effectiveness in people with pancreatic ductal cancer.
SeoulAges 20–80 - NCT07320586RecruitingPhase 2
Carilizumab and chemo for advanced gastric cancer
This trial tests a combination of carilizumab (an immunotherapy) and albumin paclitaxel (a chemotherapy drug) for people with advanced stomach or gastroesophageal junction cancer that has gotten worse after first-line treatment. It aims to see if this second-line option can help control the cancer.
Jinan, ShandongAges 18–75 - NCT07310069Enrolling by invitationPhase 2
Testing a new drug combination for advanced gallbladder cancer
This trial tests a combination of two chemotherapy drugs (gemcitabine and nab-paclitaxel) with two immunotherapy drugs (iparomlimab and tuvorilimab) for people with advanced gallbladder cancer that cannot be removed by surgery. The goal is to see if this combination can help shrink the cancer or slow its growth.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT06888843RecruitingPhase 2
Chemotherapy for colorectal cancer in patients 70+
This trial tests two chemotherapy drugs, capecitabine alone or with oxaliplatin, in people aged 70 or older after surgery for stage III colorectal cancer. The goal is to find out which treatment works better to prevent cancer from coming back.
Nizhny NovgorodAges 70–90 - NCT06313983RecruitingPhase 3
Study of hemay022 plus hormone therapy for advanced breast cancer
This trial tests a new targeted drug (hemay022) combined with an aromatase inhibitor (a type of hormone therapy) for people with advanced breast cancer that is both hormone-receptor-positive and HER2-positive. It may be an option if you've already tried trastuzumab or a similar treatment and it stopped working.
BeijingAges 18 years+ - NCT05827796RecruitingPhase 1/Phase 2
Testing IN10018 plus chemo with an added antibody in pancreatic cancer
This Phase 1/2 trial tests a new medicine (IN10018) and a specific added antibody (KN046) together with standard chemotherapy for advanced pancreatic cancer. It aims to see whether this combination can better control the cancer and how safely it can be given.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT05908643RecruitingPhase 1/Phase 2
First test of pTTL for advanced colorectal cancer
This trial tests pTTL, a personalized cancer treatment made from your tumor and immune cells, in people with advanced (stage IV) colorectal cancer. It’s designed to see whether pTTL is safe and potentially effective when standard treatments have been used or can’t be used.
Stockholm, Stockholm CountyAges 18 years+ - NCT07040228RecruitingPhase 1/Phase 2
Study of regorafenib, toripalimab, and chemo for advanced pancreatic cancer
This trial tests a combination of three drugs (regorafenib, toripalimab, and albumin-bound paclitaxel) as a third-line treatment for advanced pancreatic cancer that has progressed after two prior therapies. The goal is to see if this combination can help shrink tumors or slow the cancer's growth.
Shenzhen, GuangdongAges 18–80 - NCT06954584RecruitingPhase 3
Fluzoparib with or without bevacizumab or diet for advanced ovarian cancer
This trial tests if adding bevacizumab (a drug that blocks blood vessel growth) or a special diet to fluzoparib (a PARP inhibitor) works better than fluzoparib alone for women with advanced ovarian cancer whose tumors have specific genetic features (HRD-positive or HRD-negative). It is for patients who have already responded well to initial chemotherapy.
Wuhan, HubeiAges 18 years+ - NCT06926140Recruiting
Acupuncture with immunotherapy for advanced lung cancer
This trial tests if adding acupuncture to standard immunotherapy and chemotherapy helps people with advanced lung cancer. It is for those who have not had treatment before and whose tumors have low PD-L1 levels.
Hefei, AnhuiAges 18–75 - NCT05578053Recruiting
Dalpiciclib for hormone receptor–positive advanced breast cancer
This trial studies whether dalpiciclib can slow down or control advanced hormone receptor–positive breast cancer and assess how safe it is. It’s for people whose cancer has come back in a limited way or spread and can’t be fully cured with surgery or radiation.
Shijiazhuang, HebeiAges 18 years+ - NCT06368141RecruitingPhase 2
Chemo plus immunotherapy before surgery for colon cancer
This trial tests whether giving chemotherapy followed by an immunotherapy drug (a checkpoint inhibitor) before surgery helps shrink locally advanced colon cancer. It is for people with a specific tumor type (MSS and RAS mutation) who have not had prior treatment.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT06128252Recruiting
Taurine with chemotherapy and immunotherapy for gastric cancer
This trial tests whether adding taurine to standard chemo-immunotherapy before surgery helps treat locally advanced gastric cancer. It may be an option for patients whose tumors are PD-L1 positive and can be fully removed with surgery.
Wuhan, HubeiAges 18–75 - NCT05226169RecruitingPhase 3
Iron medicine plus standard therapy for advanced stomach cancer
This Phase 3 study tests whether giving ferric carboxymaltose (an IV iron treatment) helps people with advanced stomach or stomach–esophagus cancer and iron-deficiency anemia. The goal is to improve safety and how well the standard first-line cancer treatment works.
SeoulAges 19 years+ - NCT04107077RecruitingPhase 2
HIPEC surgery plus chemotherapy for advanced stomach cancer
This study tests whether a specialized surgery called HIPEC (heat-treated chemotherapy placed in the belly) can improve outcomes for people with advanced stomach cancer that has reached the lining of the abdomen. It’s given after you’ve already had standard chemotherapy, aiming to better control disease in the belly.
Chicago, IllinoisAges 18 years+ - NCT04891016RecruitingPhase 2
Immunotherapy with chemotherapy for locally advanced stomach cancer
This trial studies toripalimab (an immune system medicine) plus FLOT chemotherapy in people with stomach cancer that has grown locally but hasn’t spread to distant organs. It aims to improve control of the cancer and help more people have their tumors fully treated.
Zhengzhou, HenanAges 18–70 - NCT07452224RecruitingPhase 2
Combination treatment for advanced lung cancer
This trial tests a new drug, ILKN421H, combined with pembrolizumab (a type of immunotherapy) for people with advanced non-small cell lung cancer (NSCLC) that has not responded to standard treatments or has not been treated before. It aims to see if this combination can help shrink tumors or slow their growth.
Los Angeles, CaliforniaAges 18 years+ - NCT03259867RecruitingPhase 2
TACE plus immune therapy for liver or stomach cancer
This trial tests a combination treatment using a targeted liver procedure plus an immune “checkpoint” medicine to slow cancer growth. It may help people with advanced liver cancer (HCC) or metastatic stomach cancer when standard treatments have not worked.
Orange, CaliforniaAges 18–80 - NCT06776757RecruitingPhase 1/Phase 2
Sintilimab plus cetuximab and chemo for first-line advanced colorectal cancer
This trial tests a combination of immunotherapy (sintilimab), a targeted therapy (cetuximab), and chemotherapy as a first treatment for advanced colorectal cancer that hasn't spread or come back after earlier treatment. It's for people whose tumors have certain genetic markers (RAS/BRAF wild-type) and show signs of immune activity (PD-L1 or CD8+ TILs).
Shenzhen, GuangdongAges 18–75 - NCT06998108RecruitingPhase 3
A new drug with fulvestrant for HR+/HER2- advanced breast cancer
This trial tests a new investigational drug called BEBT-209 combined with fulvestrant (a hormone therapy) versus placebo with fulvestrant for people with a type of breast cancer that is hormone receptor-positive and HER2-negative. It is for those whose cancer has worsened after previous hormone therapy and has spread locally or to other parts of the body.
Beijing, Beijing MunicipalityAges 18 years+ - NCT06866262RecruitingPhase 1/Phase 2
Inulin gel with immunotherapy for advanced kidney cancer
This trial tests whether adding an inulin gel to standard immunotherapy (ipilimumab and nivolumab) can help treat kidney cancer that has spread or cannot be removed. It is for people who have not had prior treatment for advanced disease.
Ann Arbor, MichiganAges 18 years+ - NCT06910722Recruiting
Liver transplant for bile duct cancer after treatment
This trial tests if a liver transplant can help people with a certain type of bile duct cancer (intrahepatic cholangiocarcinoma) that cannot be removed by surgery. Before the transplant, you would receive radiation therapy (SIRT) and chemotherapy to shrink the tumor.
Clichy-sous-BoisAges 18–65 - NCT06422403RecruitingPhase 2
Study on giving immunotherapy less often for advanced cancer
This trial tests whether giving certain immunotherapy drugs less often than usual is safe and still works well for people with advanced stomach, liver, or lung cancer. It might mean fewer hospital visits while still controlling the cancer.
SingaporeAges 21–99 - NCT07179692RecruitingPhase 1
CEA-targeted CAR-T therapy for advanced solid tumors
This trial tests a type of immunotherapy called CAR-T, which is designed to recognize and attack cancer cells that have a protein called CEA on their surface. It's for people with advanced cancers like colorectal, esophageal, gastric, pancreatic, lung, or bile duct cancer who have tried at least two standard treatments.
Hefei, AnhuiAges 18 years+
Hear when a new Advanced Liver Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for advanced liver cancer?
- Yes. Clin2 currently lists 862 recruiting advanced liver cancer studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a advanced liver cancer trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a advanced liver cancer trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.